Sensus Healthcare, Inc. (NASDAQ:SRTS) Sees Large Decline in Short Interest

Sensus Healthcare, Inc. (NASDAQ:SRTS) was the target of a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 486,100 shares, a decrease of 18.1% from the November 15th total of 593,700 shares. Based on an average daily volume of 161,300 shares, the days-to-cover ratio is presently 3.0 days. Approximately 3.7% of the shares of the stock are short sold.

Sensus Healthcare Price Performance

Sensus Healthcare stock traded down $0.17 during mid-day trading on Monday, hitting $7.99. 148,403 shares of the company’s stock traded hands, compared to its average volume of 273,663. The firm has a 50 day simple moving average of $7.46 and a two-hundred day simple moving average of $6.45. Sensus Healthcare has a fifty-two week low of $2.15 and a fifty-two week high of $9.33. The stock has a market cap of $130.96 million, a price-to-earnings ratio of 14.32 and a beta of 1.16.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. HC Wainwright boosted their price target on shares of Sensus Healthcare from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, November 18th. Maxim Group raised their target price on Sensus Healthcare from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Friday, November 15th.

Hedge Funds Weigh In On Sensus Healthcare

Large investors have recently made changes to their positions in the company. Renaissance Technologies LLC grew its position in Sensus Healthcare by 34.4% during the 2nd quarter. Renaissance Technologies LLC now owns 391,534 shares of the company’s stock worth $2,087,000 after acquiring an additional 100,294 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Sensus Healthcare by 128.0% in the second quarter. Dimensional Fund Advisors LP now owns 166,590 shares of the company’s stock worth $888,000 after purchasing an additional 93,511 shares during the period. Marshall Wace LLP raised its holdings in shares of Sensus Healthcare by 152.4% during the second quarter. Marshall Wace LLP now owns 77,387 shares of the company’s stock valued at $412,000 after purchasing an additional 46,732 shares during the period. Acadian Asset Management LLC raised its stake in Sensus Healthcare by 578.6% during the 2nd quarter. Acadian Asset Management LLC now owns 45,124 shares of the company’s stock worth $239,000 after buying an additional 38,474 shares during the period. Finally, Cubist Systematic Strategies LLC bought a new position in Sensus Healthcare in the second quarter worth approximately $156,000. Institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.